| Summary: | Our objective was to assess the impact of treatment with risedronate on the bone mineral density and quality of life in the women who had postmenopausal osteoporosis (PMO).
Sixty-five patients with PMO were included in the study. Forty-five of them were selected randomly, and constituted the study group while the remaining 20 served as control. Forty-five patients comprising the study group were treated with 5 mg risedronate and 1000 mg calcium for 1 year while 20 control patients were treated only with 1000 mg calcium. The quality of life of the patients was evaluated with Notthingham Health Profile (NHP) scale both at the beginning and at the end of the study. Bone mineral densities were measured in the vertebral and femoral regions using DEXA at the beginning, and at 6th and 12th months of the treatment. The results of patients and controls were not different significantly after 6 months follow up (p>0.05). At the end of 1 year follow up, the bone mineral density of the treatment group increased significantly while it decreased significantly in the controls (p<0.05).
Quality of life increased significantly in the treatment group (p<0.05) while it did not change in the control group (p>0.05). The parameters related to the limitation of physical activity did not change significantly in the treatment group (p>0.05). In conclusion, by increasing the bone mineral density, risedronate increases the quality of bone, decreases the risk of fracture and pain, and positively effects the quality of life.
|
|---|